Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Flagellin type B (FliC) is the primary structural subunit of the flagellar filament in Pseudomonas aeruginosa, a major opportunistic pathogen. It is a multifunctional protein responsible for bacterial motility, chemotaxis, and initial attachment to host surfaces, which are critical steps for establishing infection [UniProt P02968]. The FliC protein is organized into domains D0, D1, D2, and D3; while D0 and D1 are highly conserved and responsible for Toll-like receptor 5 (TLR5) recognition, the D2 and D3 domains are hypervariable and project outward from the filament surface, serving as major targets for the host's adaptive immune response [PubMed: 15153205, PubMed: 11113294]. In clinical settings, Flagellin B is a key virulence factor involved in the pathogenesis of cystic fibrosis and hospital-acquired infections, as it triggers potent pro-inflammatory responses through the TLR5 and NLRC4 inflammasome pathways [PubMed: 22434327]. As a therapeutic target, the D2 subunit/domain is primarily utilized in the development of subunit vaccines and neutralizing antibodies aimed at inhibiting bacterial movement and promoting opsonophagocytosis [PubMed: 24391942]. However, the significant sequence diversity within the D2 domain across different Pseudomonas strains presents a challenge for achieving broad-spectrum efficacy [PubMed: 28863240].
Neutralization of motility and colonization through antibody binding; induction of protective immunity; activation of TLR5-mediated cytokine production for adjuvant effects.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Flagellin type B (FliC) (FliC).